Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $16.79

Key Points

• Pediatrix Medical Group, Inc. (NYSE:MD) has received an average consensus rating of “Moderate Buy” from analysts, with five holding recommendations, two buys, and one strong buy.
• The stock's average 1-year price target is $16.7857, reflecting recent target revisions from various analysts, including upgrades from Leerink Partners and Zacks Research.
• Pediatrix Medical Group reported $0.53 earnings per share for the last quarter, exceeding expectations, but saw a 7.1% decline in revenue compared to the previous year.

Shares of Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $16.7857.

Several brokerages recently issued reports on MD. Wall Street Zen lowered shares of Pediatrix Medical Group from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Zacks Research upgraded shares of Pediatrix Medical Group to a "strong-buy" rating in a research note on Monday, August 11th. UBS Group increased their price target on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research note on Thursday, August 14th. Finally, Leerink Partners increased their price target on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a "market perform" rating in a research note on Friday, September 5th.

Pediatrix Medical Group Trading Down 2.0%

NYSE MD traded down $0.34 during trading on Monday, hitting $16.67. The company had a trading volume of 524,924 shares, compared to its average volume of 774,244. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70. Pediatrix Medical Group has a one year low of $10.39 and a one year high of $17.67. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 12.92 and a beta of 1.30. The company's fifty day moving average is $14.75 and its 200-day moving average is $14.17.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.11. The company had revenue of $468.84 million during the quarter, compared to analyst estimates of $464.37 million. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. Pediatrix Medical Group's quarterly revenue was down 7.1% compared to the same quarter last year. During the same period last year, the business earned $0.34 EPS. On average, sell-side analysts predict that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors and hedge funds have recently bought and sold shares of MD. Nuveen LLC bought a new stake in Pediatrix Medical Group during the 1st quarter valued at about $8,024,000. Ameriprise Financial Inc. increased its stake in Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company's stock valued at $10,683,000 after purchasing an additional 474,186 shares in the last quarter. American Century Companies Inc. increased its stake in Pediatrix Medical Group by 28.6% during the 2nd quarter. American Century Companies Inc. now owns 1,931,867 shares of the company's stock valued at $27,722,000 after purchasing an additional 430,029 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Pediatrix Medical Group by 669.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company's stock valued at $6,832,000 after purchasing an additional 414,216 shares in the last quarter. Finally, Hillsdale Investment Management Inc. increased its stake in Pediatrix Medical Group by 75,200.0% during the 2nd quarter. Hillsdale Investment Management Inc. now owns 376,500 shares of the company's stock valued at $5,403,000 after purchasing an additional 376,000 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.